Indications:
For potassium replacement in the case of:
· pronounced hypokalaemia (< 3.2 mmol/l), particularly in the case of simultaneous metabolic acidosis.
· hypokalaemic neuromuscular disorders or heart rhythm disorders.
· hypokalaemia with simultaneous Digitalis treatment.
For prophylaxis for hypokalaemia due to ketoacidosis.
For kidney stone metaphylaxis due to:
· Calcium stones (e.g. due to renal tubular acidosis).
· Hypocitraturia (< 320 mg/d) of various origins.
· Uric acid stones.
Contraindications:
Hypersensitivity to the active substances or to any of the excipients.
Kalinor effervescent tablets should not be used in the case of conditions that are often linked to hyperkalaemia:
· Dehydration
· Restricted excretory renal function
· Addison's disease
· Adynamia episodica hereditaria
Pregnancy and breastfeeding:
There is no known information on harmful effects during pregnancy and lactation. As both high and low potassium serum levels impair maternal and foetal heart function, the maternal serum level should be monitored closely. Provided that the maternal serum level remains within the physiological range, no harmful effects are to be expected for the embryo, foetus or breastfed child.
Side effects:
Uncommon (≥ 1/1,000 to < 1/100):
Heartburn, stomach pain, diarrhoea, eructation, nausea/vomiting, flatulence
Rare (≥ 1/10,000 to < 1/1,000):
Allergic reactions, such as: Eczema, pruritis, rash, facial swelling. In this case, the preparation must be discontinued, Hyperkalaemia
Very rare (< 1/10,000):
Excessive intake rates of potassium can lead to disturbances to cardiac rhythm.
Dosage and administration:
- For potassium replacement: The dosage is determined by the deficit to be replaced; 40–80 mmol potassium per day is usually adequate. No more than 160 mmol per day should be given. The individual dose should not be more than 40 mmol potassium – corresponding to 1 Kalinor effervescent tablet.
- For kidney stone metaphylaxis: The dosage should be selected by the doctor treating the patient so that the citrate excretion is greater than 320 mg daily and a urine pH of 6.2–6.8 is achieved. These values can be reached with a dose of 1–2 effervescent tablets. The individual dose should not be more than one Kalinor effervescent tablet, corresponding to 40 mmol potassium.
The daily dose should not exceed 4 effervescent tablets, corresponding to 160 mmol potassium/day. A daily dose of 2 or more effervescent tablets should be taken, divided across the day. If the cause of a potassium deficit cannot be determined, ongoing replacement is recommended. In other cases of potassium deficiency, days to weeks often suffice to balance the potassium deficit.
To be swallowed (after dissolving). Dissolve 1 Kalinor effervescent tablet in a glass of water (200 ml) and sweeten with sugar or fruit juice as required. Drink in sips over 10–15 minutes. Taking at mealtimes improves gastrointestinal tolerance.
